Connect Biopharma Announces First Subject Dosed in Phase I Trial Evaluating Safety, Tolerability and Pharmacokinetic Profile ...
May 25 2021 - 8:00AM
Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect
Biopharma" or the “Company”), a global clinical-stage
biopharmaceutical company dedicated to improving the lives of
patients with chronic inflammatory diseases through the development
of therapies derived from T cell-driven research, today announced
that the first subject has been dosed in a Phase I trial evaluating
CBP-174 in healthy adult subjects.
This randomized, double-blind,
placebo-controlled, single ascending dose trial in healthy
subjects, aims to evaluate the safety, tolerability and
pharmacokinetics of CBP-174 in different dose levels given orally,
compared to placebo. Following the single dose, each subject will
be followed for up to seven days (NCT04811469).
“The effective management of pruritus associated
with atopic dermatitis and other inflammatory skin conditions
remains a significant unmet medical need, and the advancement of
this novel oral agent into Phase I trial is an important step
forward in the development of potential therapies,” said Zheng Wei,
PhD, Co-founder and CEO of Connect Biopharma. “We believe that
CBP-174’s novel mechanism of action and rapid onset of action has
the potential to complement the anti-pruritic effect of
disease-modifying agents already approved for inflammatory skin
diseases.”
About Chronic Inflammatory
Pruritus
Chronic inflammatory pruritus is an unpleasant
and often persistent itch that can last more than six weeks in
duration and is often caused by inflamed skin lesions associated
with diseases such as atopic dermatitis (AD). Due to the
significant impact that pruritus has on quality of life, its
severity is often measured by patients based on intensity of
pruritus rather than skin lesions themselves. Common antihistamine
drugs primarily target the histamine 1 receptor (H1R) and lead to
alleviation of itch in part by blocking H1R on peripheral nerves.
However, many types of chronic itch cannot be relieved by current
antihistamine treatments that target H1R. Despite currently
available treatments for AD, an estimated 40% to 50% of AD patients
have inadequate relief of their pruritus and are in need of new,
efficacious pruritus therapies.
About CBP-174
CBP-174 is a highly potent, orally active,
peripherally restricted antagonist of histamine receptor 3 (H3R),
designed not to penetrate the blood brain barrier. In preclinical
studies, CBP-174 was both well-tolerated and demonstrated
significant reductions in scratching bouts within the first 30
minutes of oral or topical dosing, which could potentially
translate to rapid relief of itch in the clinic.
About Connect Biopharma Holdings
Limited
Connect Biopharma Holdings Limited is a global
clinical-stage biopharmaceutical company dedicated to improving the
lives of patients living with chronic inflammatory diseases through
the development of therapies derived from our T cell-driven
research.
Our lead product candidate, CBP-201, is an
antibody designed to target interleukin-4 receptor alpha (IL-4Rα)
and is currently being evaluated in clinical trials for the
treatment of atopic dermatitis (AD) and asthma and in development
for chronic rhinosinusitis with nasal polyps (CRSwNP). Our second
lead product candidate is CBP-307, a modulator of a T cell receptor
known as sphingosine 1-phosphate receptor 1 (S1P1) that is in
development for the treatment of ulcerative colitis (UC) and
Crohn’s disease (CD). Furthermore, we are developing CBP-174, a
peripherally restricted antagonist of histamine receptor 3, for the
treatment of pruritus associated with skin inflammation.
With headquarters in China, additional
operations in the United States and Australia, and clinical
development activities in those geographies as well as Europe,
Connect Biopharma is building a rich global pipeline of internally
designed, wholly owned small molecules and antibodies targeting
several aspects of T cell biology. For additional information about
Connect Biopharma, please visit our website at
www.connectbiopharm.com.
FORWARD-LOOKING STATEMENTS
Connect Biopharma cautions that statements
included in this press release that are not a description of
historical facts are forward-looking statements. Words such as
"may," "could," "will," "would," "should," "expect," "plan,"
"anticipate," "believe," "estimate," "intend," "predict," "seek,"
"contemplate," "potential," "continue" or "project" or the negative
of these terms or other comparable terminology are intended to
identify forward-looking statements. These statements include the
Company's statements regarding the potential of CBP-174 to address
the unmet needs of patients with chronic inflammatory pruritus. The
inclusion of forward-looking statements should not be regarded as a
representation by Connect Biopharma that any of its plans will be
achieved. Actual results may differ from those set forth in this
release due to the risks and uncertainties inherent in the Connect
Biopharma business and other risks described in the Company's
filings with the Securities and Exchange Commission ("SEC").
Investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and Connect Biopharma undertakes no obligation to revise or update
this news release to reflect events or circumstances after the date
hereof. Further information regarding these and other risks is
included in Connect Biopharma's filings with the SEC which are
available from the SEC's website (www.sec.gov) and on Connect
Biopharma's website (www.connectbiopharm.com) under the heading
"Investors." All forward-looking statements are qualified in their
entirety by this cautionary statement. This caution is made under
the safe harbor provisions of Section 21E of the Private Securities
Litigation Reform Act of 1995.
IR/PR Contacts:Lazar FINN Partners David
Carey (IR) T: +1-(212)
867-1768david.carey@finnpartners.com
Erich Sandoval (Media)T:
+1-(917)-497-2867erich.sandoval@finnpartners.com
Corporate
Contacts:info@connectpharm.com
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From Apr 2023 to Apr 2024